Markus Warmuth Sells 5,466 Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) CEO Markus Warmuth sold 5,466 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $17.92, for a total value of $97,950.72. Following the transaction, the chief executive officer directly owned 613,471 shares in the company, valued at approximately $10,993,400.32. The trade was a 0.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Markus Warmuth also recently made the following trade(s):

• On Wednesday, January 7th, Markus Warmuth sold 5,466 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $23.49, for a total value of $128,396.34.

Monte Rosa Therapeutics Trading Up 3.6%

NASDAQ:GLUE traded up $0.65 during mid-day trading on Wednesday, reaching $18.61. The company’s stock had a trading volume of 567,619 shares, compared to its average volume of 1,811,703. The stock has a market cap of $1.21 billion, a P/E ratio of 58.16 and a beta of 1.63. The firm’s fifty day moving average price is $19.95 and its two-hundred day moving average price is $13.87. Monte Rosa Therapeutics, Inc. has a 12-month low of $3.50 and a 12-month high of $25.77.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. GAMMA Investing LLC purchased a new stake in shares of Monte Rosa Therapeutics in the 4th quarter worth $30,000. Russell Investments Group Ltd. purchased a new position in Monte Rosa Therapeutics during the third quarter valued at $32,000. Lazard Asset Management LLC raised its stake in shares of Monte Rosa Therapeutics by 42.9% in the second quarter. Lazard Asset Management LLC now owns 10,857 shares of the company’s stock worth $48,000 after buying an additional 3,262 shares during the period. Nisa Investment Advisors LLC increased its holdings in Monte Rosa Therapeutics by 16.7% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock worth $49,000 after acquiring an additional 451 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in Monte Rosa Therapeutics by 32.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock valued at $50,000 after purchasing an additional 776 shares in the last quarter. Hedge funds and other institutional investors own 79.96% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on GLUE shares. Jefferies Financial Group restated a “buy” rating and issued a $31.00 target price on shares of Monte Rosa Therapeutics in a report on Wednesday, January 7th. Zacks Research downgraded Monte Rosa Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 4th. Wedbush reaffirmed an “outperform” rating and issued a $37.00 price objective on shares of Monte Rosa Therapeutics in a report on Wednesday, January 7th. Piper Sandler reissued an “overweight” rating and issued a $37.00 target price (up from $27.50) on shares of Monte Rosa Therapeutics in a report on Wednesday, January 14th. Finally, Guggenheim raised their target price on Monte Rosa Therapeutics from $16.00 to $34.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Monte Rosa Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $31.33.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.